Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo's Support on Rett Syndrome Program Progress

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Taysha Gene Therapies, Inc. is placed sixth on our list of best biotech stocks under $20.

TheFly reported on January 5 that Wells Fargo raised its price target on TSHA to $11 from $8 and maintained an Overweight rating. The firm credited the anticipated 2026 outperformance to the ongoing advancements in its primary Rett syndrome research, which are bolstered by the FDA’s approval of a favorable trial design last year.

Separately, on January 6, Taysha Gene Therapies, Inc. (NASDAQ:TSHA) reported progress on its TSHA-102 Rett syndrome program. The first patient in the REVEAL pivotal phase was dosed in Q4 2025, and the FDA authorized the use of ASPIRE trial data in the proposed BLA. With updated safety and efficacy data from REVEAL Part A due in H1 2026, TSHA plans to complete dosing in both studies by Q2 2026.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical‑stage biotechnology company that develops adeno‑associated virus (AAV)‑based gene therapies for severe monogenic diseases of the central nervous system, including Rett syndrome.

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.